KJKee-Taek Jang

Kee-Taek Jang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kee-Taek Jang has a total of 324 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Guidelines for Diagnosis, Reporting and Management of Intraductal Papillary Neoplasm of the Bile Duct ( IPNB ): Recommendations of Bangkok Consensus Meeting

    by Vor Luvira, Jin‐Young Jang, Keiichi Kubota, Anon Chotirosniramit, Itaru Endo, Dhananjaya Sharma, Chawalit Pairojkul, Yasuni Nakanuma, Jong Ho Moon, Jeong Min Lee, et al.

    Background: There are no international consensus guidelines on IPNB. Method: An international‐multidisciplinary panel performed a critical appraisal of the literature and used a two‐round Delphi process to evaluate 24 critical clinical questions, incorporating community feedback from a dedicated 2025 A‐PHPBA meeting session in Bangkok. Results: Salient aspects of the recommendations: (1) IPNB is analogous to intracholecystic papillary neoplasm (ICPNs)/intraductal papillary mucinous neoplasm (IPMNs), ranging from innocuous cystic lesions to papillary in situ carcinomas to invasive carcinomas. (2) Possible etiologic factors like stones, parasites, PSC, and PBM/choledochal cysts should be assessed in every case. (3) All nonmetastatic IPNBs are candidates for oncologic resection, preferably along with lymph node dissection. (4) Pre‐ and intraoperative assessment for multifocality is important. (5) Liver transplant is a consideration in selected cases. (6) Individualized IPNB‐focused synoptic pathology reports were devised for use. (7) For invasive IPNBs, adjuvant treatment should follow standard cholangiocarcinoma protocols. (8) Follow‐up should mirror main‐duct IPMN protocols, adjusted for invasion and margin status. (9) For isolated IPNB recurrence, resection or transplant is advisable; if infeasible or metastatic, consider ablative and systemic therapies. (10) These recommendations are also applicable to IOPN/ITPN but with subtle differences. Conclusion: These recommendations should aid in cross‐national standardized classification, diagnosis, reporting, and management of IPNBs, and serve as a launching pad for further studies.

  • Open Access

    Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis

    by Minsuk Kwon, Yunjin Go, Ji Eun Shin, Sung Hee Lim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Kee-Taek Jang, Jeeyun Lee, et al.

    PURPOSE: Activating mutations in GNAQ and GNA11 are recognized oncogenic drivers in uveal melanoma (UM); however, their prevalence across various cancers and their genomic context remain inadequately characterized. This study aimed to elucidate the genomic landscape of these mutations across a range of metastatic solid tumors. MATERIALS AND METHODS: We conducted a pan-cancer analysis involving 5,416 patients with metastatic solid tumors who had undergone next-generation sequencing. Our evaluation encompassed mutational distribution, hotspot identification, tumor mutational burden (TMB), microsatellite instability (MSI), and coalterations. RESULTS: Mutations in GNAQ (n = 10) or GNA11 (n = 16) were detected in 26 patients (0.48%). Aside from UM, these mutations were most frequently observed in colorectal cancer (38.5%), melanoma (15.4%), gastric cancer (11.5%), and neuroendocrine tumors (7.7%). A notable subset exhibited an immunogenic profile, with 42.3% classified as TMB-High (≥10 Mut/Mb) and 19.2% as MSI-High. This immunogenic subgroup was primarily associated with nonhotspot mutations (eg, p.Gln88His, p.Ala231Val), suggesting that these may represent bystander events in hypermutated tumors. Conversely, canonical hotspots (Q209, R183) were predominantly identified in TMB-Low/microsatellite stable tumors, such as UM. Notable coalterations included NOTCH3 (80%), FAT1 (70%), and TP53 (37.5%-40%). Exploratory survival analysis suggested favorable OS in the immunogenic subgroup, supported by cases with durable ICI benefit including a treatment-free remission exceeding 21 months. CONCLUSION: This real-world analysis demonstrates that GNAQ and GNA11 mutations are not exclusive to UM, occurring across diverse solid tumors, particularly colorectal cancer. The strong association between nonhotspot mutations and high TMB/MSI status defines a distinct immunogenic subgroup, underscoring the need to differentiate canonical hotspot drivers from bystander mutations when selecting targeted pathway inhibitors versus immune checkpoint blockade.

  • Open Access

    Malignant epithelial states drive immune dysfunction in ampulla of Vater carcinoma

    by Hyoung-Oh Jeong, Young Hoon Choi, Hyemin Kim, Aryoung Kim, Kyoung Jun Lee, Jaewoong Lee, Hyeong Seok Kim, Hochang Chae, Hongbeom Kim, Sang Hyun Shin, et al.

    Ampulla of Vater (AoV) carcinoma is a rare malignancy arising at the junction of intestinal and pancreatobiliary epithelium. Its heterogeneous clinical behavior and histological diversity have hindered therapeutic advances, and the cellular basis of this heterogeneity remains unclear. We aimed to construct a single-cell transcriptomic atlas of AoV carcinoma, with a focus on identifying epithelial subtypes and their interactions with the tumor microenvironment (TME). We performed single-cell RNA sequencing on eight primary AoV tumors and four matched normal tissues. Comprehensive clustering and transcriptomic analyses identified cell-type composition, epithelial heterogeneity, and tumor-immune interactions. Findings were validated using deconvolution of bulk RNA-seq data from 62 AoV carcinoma patients. Results Malignant epithelial cells were categorized into four distinct subtypes: Int-Wnt, PB-KRAS, Int-Hypoxia, and Cycling stage. PB-KRAS cells exhibited stem-like transcriptional programs and high genomic instability. Deconvolution analysis of bulk RNA-seq data from the independent AoV cohort revealed that enrichment of the PB-KRAS subtype correlated with tumor recurrence and poor survival. Our immune profiling analysis discovered a significant association between PB-KRAS subtype and GZMK+ CD8+ T cells, which are in a pre-dysfunctional state, alongside SPP1+ macrophages exhibiting immunosuppressive traits. Spatial transcriptome data further supports the immunosuppressive natures of TME around PB-KRAS subtype malignant epithelial cells in AoV carcinoma. Our study presents a single-cell atlas of AoV carcinoma, highlighting the molecular diversity of malignant epithelium and its association with the immune microenvironment. The PB-KRAS subtype emerges as a stem-like, immunosuppressive tumor state associated with poor prognosis, providing insights for future therapeutic targeting.

  • Open Access

    Large-Scale Dermatopathology Dataset for Lesion Segmentation: Model Development and Analysis

    by Yosep Chong, Daseul Park, Youngbin Ahn, Yoonjin Kwak, Seyeon Park, Seung Wan Back, Changwoo Lee, Gyeongsin Park, Mohammad Rizwan Alam, Binna Kim, et al.

    Chong Y, et al. J Korean Med Sci. 2025 Jul;40:e220. https://doi.org/10.3346/jkms.2025.40.e220


  • Open Access

    Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP

    by Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, et al.

    In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.


  • Open Access

    Prediction of Lymph Node Metastasis in T1 Colorectal Cancer Using Artificial Intelligence with Hematoxylin and Eosin-Stained Whole-Slide-Images of Endoscopic and Surgical Resection Specimens

    by Joo Hye Song, Eun Ran Kim, Yiyu Hong, Insuk Sohn, Soomin Ahn, Seok-Hyung Kim, Kee-Taek Jang

    According to the current guidelines, additional surgery is performed for endoscopically resected specimens of early colorectal cancer (CRC) with a high risk of lymph node metastasis (LNM). However, the rate of LNM is 2.1–25.0% in cases treated endoscopically followed by surgery, indicating a high rate of unnecessary surgeries. Therefore, this study aimed to develop an artificial intelligence (AI) model using H&E-stained whole slide images (WSIs) without handcrafted features employing surgically and endoscopically resected specimens to predict LNM in T1 CRC. To validate with an independent cohort, we developed a model with four versions comprising various combinations of training and test sets using H&E-stained WSIs from endoscopically (400 patients) and surgically resected specimens (881 patients): Version 1, Train and Test: surgical specimens; Version 2, Train and Test: endoscopic and surgically resected specimens; Version 3, Train: endoscopic and surgical specimens and Test: surgical specimens; Version 4, Train: endoscopic and surgical specimens and Test: endoscopic specimens. The area under the curve (AUC) of the receiver operating characteristic curve was used to determine the accuracy of the AI model for predicting LNM with a 5-fold cross-validation in the training set. Our AI model with H&E-stained WSIs and without annotations showed good performance power with the validation of an independent cohort in a single center. The AUC of our model was 0.758–0.830 in the training set and 0.781–0.824 in the test set, higher than that of previous AI studies with only WSI. Moreover, the AI model with Version 4, which showed the highest sensitivity (92.9%), reduced unnecessary additional surgery by 14.2% more than using the current guidelines (68.3% vs. 82.5%). This revealed the feasibility of using an AI model with only H&E-stained WSIs to predict LNM in T1 CRC.


  • Open Access

    Practice guidelines for managing extrahepatic biliary tract cancers

    by Hyung Sun Kim, Mee Joo Kang, Jingu Kang, Kyubo Kim, Bohyun Kim, Seong-Hun Kim, Soo Jin Kim, Yong-Il Kim, Joo Young Kim, Jin Sil Kim, et al.

    Hyung Sun Kim, Mee Joo Kang, Jingu Kang, Kyubo Kim, Bohyun Kim, Seong-Hun Kim, Soo Jin Kim, Yong-Il Kim, Joo Young Kim, Jin Sil Kim, Haeryoung Kim, Hyo Jung Kim, Ji Hae Nahm, Won Suk Park, Eunkyu Park, Joo Kyung Park, Jin Myung Park, Byeong Jun Song, Yong Chan Shin, Keun Soo Ahn, Sang Myung Woo, Jeong Il Yu, Changhoon Yoo, Kyoungbun Lee, Dong Ho Lee, Myung Ah Lee, Seung Eun Lee, Ik Jae Lee, Huisong Lee, Jung Ho Im, Kee-Taek Jang, Hye Young Jang, Sun-Young Jun, Hong Jae Chon, Min Kyu Jung, Yong Eun Chung, Jae Uk Chong, Eunae Cho, Eui Kyu Chie, Sae Byeol Choi, Seo-Yeon Choi, Seong Ji Choi, Joon Young Choi, Hye-Jeong Choi, Seung-Mo Hong, Ji Hyung Hong, Tae Ho Hong, Shin Hye Hwang, In Gyu Hwang, Joon Seong Park. Ann Hepatobiliary Pancreat Surg 2024;28:161-202. https://doi.org/10.14701/ahbps.23-170


  • Open Access

    Prognostic Value of Retinoblastoma in Small Intestinal Adenocarcinoma: A Multicenter Retrospective Study

    by Sun-Young Jun, Seung-Mo Hong, Kee-Taek Jang

    Jun SY, et al. J Korean Med Sci. 2024 Dec;39:e335. https://doi.org/10.3346/jkms.2024.39.e335


  • Open Access

    Prognostic Significance of Cyclin D1 Expression in Small Intestinal Adenocarcinoma

    by Sun-Young Jun, Seung-Mo Hong, Kee-Taek Jang

    Cyclin D1, a critical cyclin-dependent kinase (CDK) 4/6-dependent regulator of G1/S transition, has attracted much interest as a therapeutic target. The cyclin D1 expression in small intestinal adenocarcinomas (SIACs) has not yet been comprehensively studied, owing to the rarity of this tumor. We investigated the clinicopathological and prognostic significance of the cyclin D1 expression in 232 surgically resected primary SIACs through a multi-institutional study. A high expression of cyclin D1 (cyclin D1High) was detected in 145 SIAC cases (63%), which was significantly higher than that in normal small intestinal mucosa (11%). Cyclin D1High was more commonly found in SIACs with a lower T-category and disease stage and KRAS mutation and predicted better patient survival. Multivariate analysis revealed that cyclin D1High, the absence of retroperitoneal seeding and lymphovascular invasion, and the lower N-category were identified as independent prognostic indicators for patients with SIACs. Specifically, cyclin D1High affected patient survival in the lower stage group (stages I and II). In conclusion, cyclin D1 was commonly overexpressed in SIACs, and cyclin D1High acted as a favorable prognostic indicator in patients with SIACs. These findings in SIACs may, thus, be important to further comprehend the mechanism of cyclin D1 in carcinogenesis and to strategize appropriate patient therapies.


  • How to interpret the high-grade dysplasia in bile duct margin of biliary tract cancer

    by Kee-Taek Jang

    Kee-Taek JANG*. Ann Hepatobiliary Pancreat Surg 2023;27:S112. https://doi.org/10.14701/ahbps.2023S1.BP-DB-1